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Abstract
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The order Mononegavirales includes five families: Bornaviridae, Filoviridae, Nyamaviridae,
Paramyxoviridae, and Rhabdoviridae. The genome of these viruses is one molecule of negativesense single strand RNA coding for five to ten genes in a conserved order. The RNA is not
infectious until packaged by the nucleocapsid protein and transcribed by the polymerase and cofactors. Reverse genetics approaches have answered fundamental questions about the biology of
Mononegavirales. The lack of icosahedral symmetry and modular organization in the genome of
these viruses has facilitated engineering of viruses expressing fluorescent proteins, and these
fluorescent proteins have provided important insights about the molecular and cellular basis of
tissue tropism and pathogenesis. Studies have assessed the relevance for virulence of different
receptors and the interactions with cellular proteins governing the innate immune responses.
Research has also analyzed the mechanisms of attenuation. Based on these findings, ongoing
clinical trials are exploring new live attenuated vaccines and the use of viruses re-engineered as
cancer therapeutics.
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Mononegavirales: non-segmented negative strand RNA viruses
Non-segmented negative strand RNA viruses (NS-NSVs) are a large group of different
viruses found both in animals and plants. NS-NSVs include several major human, animal,
and plant pathogens that have a great impact on human health and are commercially very
important. The order of Mononegavirales contains 5 families: Bornaviridae, Filoviridae,
Nyamiviridae, Paramyxoviridae, and Rhabdoviridae (Taxonomy, 2013) (Fig. 1).
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The Bornaviridae family includes only one genus Bornavirus. Borna disease virus (BDV)
causes severe neurobehavioral changes in horses and sheep; there are conflicting reports
about BDV infecting humans and causing disease (for review (Kinnunen et al., 2013)).
Interestingly, BDV replicates in the nucleus of the infected cell. Nevertheless, BDV has the
typical genome organization of a NS-NSV (Fig. 2) with a nucleoprotein (N), polymerase
cofactor (X/P), matrix protein (M), surface glycoprotein (G) and polymerase (L).

Author Manuscript

The family Filoviridae was named after the Latin noun filum meaning “thread” because of
their long “thread-like” virions of up to 800–1200 nm. The genome organization generally
follows the pattern of other NS-NSV wherein VP35 is the polymerase cofactor and VP40 is
the matrix protein (Fig. 2). Ebola virus (EBOV) recently caused a large outbreak in West
Africa with thousands of deaths and worldwide repercussions. The Filoviridae family was
reclassified in 2014 into three genera (Ebolavirus, Marburgvirus, and Cuevavirus) with the
former two of them being most important for human disease (Kuhn et al., 2014).
The new family Nyamiviridae (Taxonomy, 2013) contains the single genus Nyavirus with
the two species Nyamanini virus (NYMV) and Midway virus, which were isolated from
insects and birds (Mihindukulasuriya et al., 2009). Like BDV, NYMV replicates in the
nucleus (Herrel et al., 2012).

Author Manuscript

The Paramyxoviridae family is large and divided into two subfamilies, Paramyxovirinae
and Pneumovirinae. The latter includes two genera, Pneumovirus, which includes human
Respiratory syncytial virus (RSV), an important human pathogen discussed in more detail
below. The other genus is Metapneumovirus, which includes the important pathogen human
Metapneumovirus (hMPV). Interestingly, hMPV and RSV do cause a very similar disease.
hMPV was isolated for the first time in 2001, but nevertheless might be the second most
important virus for lower respiratory tract infection in humans after RSV (for review
(Falsey, 2008)). An unusual feature for Pneumovirinae compared to other NS-NSVs is that
they encode two nonstructural proteins (NS1 and NS2), which are located upstream of the
nucleoprotein within the genome (Fig. 2) and interfere with the host innate immunity.

Author Manuscript

The other subfamily, Paramyxovirinae is divided into seven genera, two of them including
several viruses of great importance for human and animal health. Typically, viruses of the
Paramyxovirinae subfamily encode six or seven genes. Viruses are divided into different
genera depending on two characteristics: (1) expression of one or two additional proteins
(called V and C) from their P gene; and (2) neuraminidase activity of the attachment
glycoprotein (hemagglutinin, H or hemagglutinin-neuraminidase, HN) (Lamb and Parks,
2013). A fairly newly discovered fish-infecting paramyxovirus, Atlantic salmon
paramyxovirus, established the new genus Aquaparamyxovirus. Avian paramyxoviruses,
among them the species prototype Newcastle disease virus (NDV) form the genus
Avulavirus. Fer-de-Lance paramyxovirus is a reptile virus and represents the genus
Ferlavirus. The two viruses in the Henipavirus genus, Hendra (HeV) and Nipah virus (NiV)
are emerging infectious pathogens naturally harbored by bats, but highly pathogenic when
transmitted to human or other mammals, causing respiratory or neurological diseases.
Distinct from other viruses in the subfamily, the attachment protein is not called H, but
simply glycoprotein (G). The genus Morbillivirus consists of closely related, but highly
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host-specific viruses including Measles virus (MeV), Canine distemper virus (CDV), and
Rinderpest virus (RPV). Although infecting epithelial tissues of their host, a common
feature of these viruses is lymphotropism and virus-induced immunosuppression. The
attachment protein H does not have neuraminidase activity. The genus Respirovirus includes
several parainfluenza viruses, which cause flu-like respiratory diseases. The murine
prototype, Sendai virus (SeV), is among the most important model paramyxoviruses.
Parainfluenza viruses (PIVs) type 1 and 3 are human pathogens, which are similarly
problematic as RSV and hMPV from the Pneumovirinae. The seventh genus, Rubulavirus
consists of a second group of parainfluenza viruses, among them the important human
pathogens Mumps virus (MuV), human Parainfluenza viruses type 2 and 4, and
Parainfluenza virus type 5, formerly known as Simian virus 5 (SV5). Although pathogenesis
of these viruses is similar to respiroviruses, they are grouped into a distinct genus, because
they do not express a C protein and encode a small hydrophobic membrane protein (SH).

Author Manuscript

The Rhaboviridae family contains both animal and plant viruses, which are divided into 11
genera with 71 species. The best know species infecting human and animals is Rabies virus
(RABV) of the Lyssavirus genus, which contains 13 other species causing a rabies-like
disease in most mammals. Whereas classical RABV does cause 99% of human cases, the
other species are important because the current RABV does not protect against several of
them (Evans et al., 2012). The other well-known member is vesicular stomatitis virus
(VSV), which is “the model” rhabdovirus because it has been widely used to study NS-NSV
molecular virology and biochemistry. Both Lyssavirus and Vesiculovirus have only the five
genes defining the basic NS-NSV genome organization (Fig. 2).

Author Manuscript

NS-NSVs have very specific or broad host tropism, depending on the virus. For example,
RABV has a wide host range and can infect most mammals. On the other hand, MeV infects
only certain primates. While NS-NSVs have different host(s) and tissue tropism and come in
different shapes and sizes, their genomes are similarly organized and they have, with a few
interesting variations, a similar replication process.

Replication of NS-NSVs

Author Manuscript

The genome of all NSVs is a single-stranded RNA of negative polarity, which can be one
molecule (NS-NSV) or multiple segments for segmented negative-strand RNA viruses (SNSV). Fig. 3 shows the replication cycle of RABV. The mode of replication and specific
elements required for replication and transcription are conserved for all NSVs. The
ribonucleoprotein (RNP) is the functional template for replication and transcription. As the
name suggests, RNP is RNA associated with a protein. Both the minus-strand genome and
the plus-strand anti-genome are encapsidated into the nucleoprotein (N or NP); the naked
RNA is not infectious (Conzelmann, 2004). Encapsidation follows a common mechanism
for all NSV (Green et al., 2014). This is an important feature of NSVs because such a RNPtemplate must be formed when a new virus is created de novo from cDNA. This
encapsidation step has been a major challenge to the generation of NSVs from cDNA (see
below). In order to begin replication, NSV need a complex composed of the viral
polymerase (L), the catalytic enzyme, and the non-catalytic phospoprotein (P), in addition to
the RNP (Conzelmann, 2004).
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NS-NSV transcription begins when the viral polymerase recognizes the 3′ end of the
genome and transcribes a short leader RNA followed by the viral genes. These are flanked
by conserved sequences that signal to the polymerase complex to start or stop (Fig. 3)
(Whelan et al., 2004). Transcription is not always successfully reinitiated after each stop
sequence; this lack of polymerase reinitiation results in a 3′-5′ transcription gradient. For
example, the VSV transcript levels are reduced by about 20% at each gene junction (Iverson
and Rose, 1981), and similar observations have been reported for MeV and other NS-NSVs
(Cattaneo et al., 1987).

Author Manuscript

The polymerase complex may switch to replication mode as function of the amount of N
and/or P protein available. In replication mode, the transcription start-and-stop signals are
ignored and full-length NP-encapsidated anti-genomic RNA is synthesized (Barik and
Banerjee, 1992; Gupta and Banerjee, 1997). The antigenomic RNP serves as template for
the production of more genomic RNPs. The matrix (M) protein organizes the assembly of
these genomic RNPs and the surface glycoprotein(s) and controls transcription (Whelan et
al., 2004).

Reverse genetics: how did it all begin?

Author Manuscript

The foundations for RNA virus reverse genetics were laid in 1978 by the observation that
full-length cDNA copies of bacteriophage Qbeta RNA cloned into a plasmid form plaques
after transfection of E. coli (Taniguchi et al., 1978). Three years later a similar observation
was reported for the eukaryotic Poliovirus (Racaniello and Baltimore, 1981). While the
subsequent development of reverse genetics for many more positive strand RNA viruses was
relatively straightforward, the complex mechanisms of NSV replication initially represented
a difficult barrier to overcome. However, in 1989 the Palese group showed that a marker
gene (chloramphenicol acetyl transferase, CAT) can be temporarily expressed by influenza
virus (Luytjes et al., 1989). Luytjes et al. inserted the CAT open reading between the
genomic 3′ and 5′ ends of a synthetic viral RNA, utilized purified NP and PBA, PB1, and
PB2 protein to create a synthetic RNP genome segment de novo, transfected it, and detected
CAT activity after infection with standard virus.

Author Manuscript

When attempts to recover infectious virus by encapsidating NS-NSV genomes in vitro and
transferring them into virus-infected cells failed, focus shifted to short artificial RNA
derived from the 3′ and 5′ end of the genome containing a marker gene (CAT) or to short,
naturally-occurring genomes of defective interfering (DI) viral particles. Park and Krystal
established a system to create a synthetic DI-RNA for SeV. They fused the T7 RNA
polymerase promoter 5′ to the viral genome and linearized the plasmid to generate the 3′
genome end (Park et al., 1991). After in vitro transcription, this synthetic RNA was
transfected into cells, and CAT activity was detected after helper virus infection. Collins and
colleagues reported the recovery of a RSV-derived DI with almost 50% of the genome
length (Collins et al., 1993).
In 1992, the Wertz group utilized a hepatitis delta virus (HDV)-derived ribozyme to create
an exact 3′ end of the RNA instead of just linearizing the plasmid encoding the genomic
RNA. In combination with the expression of the viral replication proteins through the
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vaccinia virus T7-RNA polymerase expression system (Fuerst et al., 1987), this resulted in
efficient and reproducible recovery of the synthetic RNP (Pattnaik et al., 1992).
Analogously, the Conzelmann group used a similar system to recover several artificial
RABV genomes expressing two different marker genes (Conzelmann and Schnell, 1994).
Importantly, recovery efficiency of these synthetic model RNAs was inversely proportional
to genome size (Conzelmann and Schnell, 1994).

A positive approach for the recovery of a negative sense RNA virus

Author Manuscript

The new approach that allowed the first successful recovery of a NS-NSV (Schnell et al.,
1994) was based on the use of anti-genomic (plus strand) rather than the genomic (minus
strand) RNA that was previously used for experiments based on synthetic DI genomes. Use
of plus-strand RNA appeared counterintuitive, but Schnell et al. were concerned that
simultaneous expression of naked negative sense genomic RNA and positive strand mRNAs
would result in hybridization and generation of double strand RNA, inducing interferon
while also reducing successful encapsidation. Indeed, RABV was rescued from a positive
strand cDNA (antigenome), but not when the negative strand genome was transcribed
(Schnell et al., 1994).

Author Manuscript

The Rose (Lawson et al., 1995) and Wertz (Whelan et al., 1995) laboratories then used
variants of the positive approach to successfully recover genetically marked recombinant
VSV and several other groups recovered recombinant viruses from the families
Paramyxoviridae and Filoviridae using similar or slightly modified systems as for RABV
(Table 1 and references therein). Several groups attempted virus recovery using both the
anti-genomic and the genomic RNA, but only the anti-genomic, positive strand RNA
worked. There has been one exception: the Nagai group recovered recombinant SeV by
expression of the negative strand genome. However, rescue efficiency from anti-genomic
RNA was about 100-fold lower than from genomic RNA (Kato et al., 1996).

Alternative recovery systems

Author Manuscript

Stable cell lines expressing the viral replication proteins have been used as alternative virus
recovery systems. The Billeter group recovered the first paramyxovirus in 1995 by using a
cell line stably expressing MeV N, P and T7 RNA polymerase (Radecke et al., 1995). After
transfection of a plasmid expressing the MeV anti-genome and a plasmid expressing MeV
L, infectious genetically marked MeV was rescued with high efficiency (Radecke et al.,
1995). Buchholz et al. generated a BHK-derived cell line stably expressing T7 RNA
polymerase and recovered a slow, replication-impaired BRSV mutant (Buchholz et al.,
1999). This indicated that the system was very efficient and remediated the cytolytic and
inhibitory effects of vaccina virus. A key parameter for efficient virus rescue is the synthesis
of genomes with correct 5′ and 3′ ends. T7-dependent transcription of viral antigenomes
added three non-virus G bases. While these bases were removed during replication, their
presence interfered with efficient RNP formation. To address this problem, Le Mercier et al.
introduced a hammer-head ribozyme (HamRz) after the GGG of the T7 promoter (Le
Mercier et al., 2002), which created an exact 5′ end, improving rescue efficiency.
McGettigan et al. introduced the sequence of HamRz into the RABV vaccine vector SPBN,
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which allowed recovery of a RABV-based vaccine construct (McGettigan et al., 2003).
Analogously, for HeV and NiV, the introduction of a HamRz in front the 5′ antigenome
greatly improved recovery efficiency (Yun et al., 2014). Moreover, use of a more efficient
HDV ribozyme to cleave the correct 3′ genome end improved the recovery frequency of
RABV 100-fold (Ghanem et al., 2012).

Author Manuscript

In summary, the recovery of NS-NSVs has come a long way. The recovery frequency for
RABV was initially ~1 focus forming unit (ffu) for 107 cell in the vaccinia-based system
(Schnell et al., 1994). It improved by a factor of 10 on T7 cells when the 3′ ends were
cleaved with a core HDV ribozyme. Precise and efficient cleavage of both ends yielded 1 ffu
for 104 cells (Ghanem et al., 2012). However, there is room for improvement. If efficiency
of the recovery improved, it would become possible to obtain even viruses with certain
classes of lethal mutations, e.g. virus particles could be recovered but would not be able to
reinfect or replicate. However for such approaches to become possible, another new key
finding, such as the use of the antigenome and the creation of the exact 3′ and 5′ end of the
genome, will be required.

Better understanding of the life cycle of NS-NSV by reverse genetics
While Mononegavirales, especially VSV, have contributed greatly to our understanding of
molecular and cell biology, their life cycle in natural hosts is less well understood. For
example, before the advent of reverse genetics, very little was known about where viruses
replicate immediately after contagion, which made it impossible to understand the series of
events leading to disease. One of the motivations for the development of reverse genetics
was to apply new experimental approaches to study tissue tropism and pathogenesis.

Author Manuscript

Fluorescent reporters expressed by recombinant viruses now provide a simple way to follow
their spread through the host organism and to identify target tissues and cell types infected.
RABV is now a widely used tool to study neuroanatomy and neuronal connection. Whereas
such study was initially performed with naturally-occurring RABV strains (Kelly and Strick,
2000), reverse genetics opened new possibilities utilizing vector with marker and modified
tropism (Wickersham et al., 2013).

Author Manuscript

For pathogenicity studies, we will focus here on the morbilliviruses MeV and CDV. How
these viruses cause immunosuppression has been a key question (Schneider-Schaulies and
Schneider-Schaulies, 2009). Until recently textbooks suggested that morbilliviruses
replicated in the epithelia in the airways immediately after contagion, and that the infection
eventually somehow caused immunosuppression. But in 2000, researchers identified a
protein expressed on the surface of immune cells, the signaling lymphocyte activation
molecule (SLAM), as the primary receptor for MeV (Tatsuo et al., 2000). One year later it
was observed that MeV entered well-differentiated primary airways epithelia much more
efficiently from the basolateral side than from the apical side (Sinn et al., 2002). Taken
together, these two observations suggested that MeV and the other morbilliviruses may take
advantage of SLAM-expressing alveolar macrophages to traverse the respiratory epithelium
immediately after contagion, allowing rapid spread in lymphatic organs and causing
immunosuppression.
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This hypothesis was tested in the ferret model with a new CDV expressing the green
fluorescent protein (GFP). Indeed it was documented that this virus replicated briskly in
local lymph nodes and primary lymphatic tissues before spreading to airways epithelia (von
Messling et al., 2004). This sequence of events was confirmed through the infection of
macaques with GFP-expressing MeV able to enter cells through either SLAM or through the
epithelial receptor nectin-4 (Lemon et al., 2011; Leonard et al., 2010, 2008; Muhlebach et
al., 2011). Thus immunosuppression occurs at least in part due to rapid, very efficient virus
replication in primary and secondary immune organs. These studies, which have
fundamentally altered our understanding of morbillivirus pathogenesis, have been made
possible by reverse genetics techniques.

Virulence: innate immunity control proteins
Author Manuscript

Viruses must control the innate immune response to replicate efficiently in a host. The
Mononegavirales do this by targeting both the interferon (IFN) induction and IFN signaling
pathways, as discussed in recent reviews (Gerlier and Lyles, 2011; Goodbourn and Randall,
2009; Parks and Alexander-Miller, 2013; Ramachandran and Horvath, 2009; Rieder and
Conzelmann, 2009; Schneider et al., 2014).

Author Manuscript

Analysis of the mechanisms by which individual viruses counteract the host innate immune
response has progressed rapidly in recent years. It has become evident that even viruses with
small genomes counteract the interferon system by interacting with several of its
components. For example, viruses of the Paramyxovirinae subfamily express either one or
both types of accessory proteins named V and C. These proteins are dispensable for virus
spread in certain transformed cell lines. However, their deletion leads to strong attenuation
in natural hosts, where infection induces adaptive immune responses of similar magnitude as
those of wild type infections (Devaux et al., 2008; Kato et al., 1997; von Messling et al.,
2006).

Author Manuscript

The V proteins of paramyxoviruses inhibit innate immune responses by binding to the
cytoplasmic double-stranded RNA (dsRNA)-receptor melanoma differentiation-associated
protein 5 (mda5), as well as the signal transducers and activators of transcription 1 and 2
(STAT1, STAT2) (Parks and Alexander-Miller, 2013). Mapping of the interaction sites of
each of these cellular proteins on the V protein of Morbilliviruses has allowed a new
approach to the assessment of the relevance of individual viral proteins for the interactions
with specific hosts. A recombinant MeV that was unable to antagonize STAT1 function was
generated, and its virulence was analyzed in rhesus monkeys (Devaux et al., 2011). This
recombinant virus could not control inflammation and was attenuated in rhesus monkeys.
On the other hand, when essentially the same study based on STAT1 interactions abrogation
was performed with CDV, it resulted in a virus that had minimal effects on CDV
pathogenesis in ferrets (Svitek et al., 2014). This finding indicated STAT1 inhibition is
insufficient to disrupt the innate immune response in vivo. On the other hand, in this virushost pair, the mda5 and STAT2 interactions played an essential role in pathogenesis, and
their ablation completely attenuated the virus (Svitek et al., 2014). Thus, even if reverse
genetics is allowing a systematic approach to the study of the relevance of different innate
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immunity interactions for virulence, the results are not always predictable. Nevertheless, this
knowledge is essential for the rational design of attenuated vaccines.

Developing new vaccines against NS-NSV: rational attenuation

Author Manuscript

The ability to recover NS-NSVs opened new areas of research. First of all, researchers were
now able to add specific mutations or exchange genes to modify the viral genome, and they
were able to analyze how such modifications affect the viral life cycle and pathogenicity of
the respective virus. Moreover, such manipulation allowed researchers to modify the virus in
such a way that new “designer vaccines” could be generated. Additionally, researchers
started to focus on using NS-NSVs as vectors for immunization against infectious diseases
by expressing foreign antigens (for review see (Bukreyev et al., 2006)). Both of these areas,
namely the generation of novel and improved NS-NSV vaccines as well the use of NSNSVs as vaccines for other pathogens grew incredibly fast in number during the past few
years. As a result, we will not be able to give a complete overview for all of the approaches,
but rather we will give some examples of such approaches.
While the MeV live attenuated vaccine, now in use for more than 50 years is very safe and
efficacious (Griffin and Pan, 2009; Katz, 2009), long standing attempts to develop vaccines
against other Mononegavirales have been less successful. In particular, RSV is notable for a
historic vaccine failure in the 1960s involving a formalin-inactivated vaccine that primed for
enhanced disease in RSV naïve recipients. Live vaccines candidates have been shown to be
free from this complication (Collins et al., 2013). However, early efforts to develop vaccines
through the classic methods of serial cold-passage yielded vaccine candidates that either
were not attenuated in young infants or had unacceptable adverse effects (Karron et al.,
2013).

Author Manuscript

A reverse genetics system for producing infectious RSV developed in 1995 (Collins et al.,
1995) was the basis for the production of all the current attenuated vaccine candidates.
Reverse genetics allowed first, to directly identify and characterize attenuating mutations in
existing attenuated strains, and second, to produce novel mutations based on functional
knowledge. Attenuating mutations can be combined to produce live-attenuated candidate
vaccines with a range of phenotypes and properties. However, the resulting levels of
attenuation cannot be predicted precisely (Karron et al., 2013, 2005). The best candidate for
a live-attenuated RSV vaccine (Phase I clinical trial NCT01893554, Table 2) so far
combines the described attenuation through temperature-sensitive mutations with additional
deletion of the NS2 gene (Luongo et al., 2013), which is a major IFN antagonist of RSV
(Bossert et al., 2003; Lo et al., 2005; Spann et al., 2005).

Author Manuscript

A different approach currently used to generate a live-attenuated vaccine for RSV is codonpair de-optimization of the genome sequence (Le Nouen et al., 2014). Existing frequent
codons in open reading frames are replaced by alternative rare codons, resulting in a highly
temperature sensitive mutant RSV (Le Nouen et al., 2014). More targeted codon deoptimization of both NS genes resulted in a genetically stable virus that was attenuated and
induced high levels of neutralizing antibodies in a mouse model (Meng et al., 2014).

Virology. Author manuscript; available in PMC 2015 November 01.

Pfaller et al.

Page 9

Author Manuscript

EBOV and MARV of the Filoviridae family target the innate immune response through
multiple mechanisms. The major IFN antagonist is the phosphoprotein VP35, which
sequesters dsRNA (Cardenas et al., 2006) and blocks the phosphorylation of IRF3 (Basler et
al., 2003). Recombinant mouse-adapted EBOV expressing VP35 with a single point
mutation making it unable to block IRF3 activation is highly attenuated in a mouse model
(Hartman et al., 2008) and therefore might represent a good candidate for vaccine
development. The IFN signaling pathway is blocked by the matrix protein VP40 of MARV,
which inhibits phosphorylation of STAT1/STAT2 (Valmas et al., 2010), or by the minor
matrix protein VP24 of EBOV, which blocks karyopherin-α-mediated nuclear import of
STAT1/STAT2 (Reid et al., 2006). How these findings can be implicated in the
development of highly attenuated vaccines needs to be determined.

Author Manuscript
Author Manuscript

In vivo attenuation of the neurotropic RABV can be achieved by targeting its IFN
antagonist, the P protein (Rieder and Conzelmann, 2009). It inhibits the activation of IRF3
(Brzozka et al., 2005) and STATs (Brzozka et al., 2006; Vidy et al., 2005). Since P is an
essential cofactor of the viral polymerase, it cannot be deleted from the virus. However, P
expression can be minimized by moving the gene behind the L gene (Brzozka et al., 2005)
or by introducing internal ribosome entry site (IRES) elements from positive strand RNA
viruses of the Picornaviridae family (Marschalek et al., 2009). The resulting viruses have
proven high attenuation in mice (Marschalek et al., 2009; Rieder et al., 2011), but whether
they protect against lethal challenge still needs to be tested. RABVs expressing P that is
unable to inhibit IRF3 activation are attenuated in wt mice, but not in IFNARko mice (Rieder
et al., 2011). One of these viruses tested as a vaccine candidate successfully protected foxes
from RABV challenge, although neutralizing antibody titers were lower than with standard
vaccine; the same virus failed to induce sufficient levels of neutralizing antibodies and
protection in skunks (Vos et al., 2011). RABV expressing a mutant form of P (W265G/
M287V) unable to interact with STAT1 was completely attenuated in ddY mice (Wiltzer et
al., 2014). When infected intracranially with this virus, mice only developed mild symptoms
and recovered completely.
The currently used VSV for reverse genetics is already attenuated compared to wild-type
VSV even though the mechanism has not been identified yet (Publicover et al., 2004). One
of the earliest rational approaches to attenuated VSV was the reduction of viral growth by
the deletion of the cytoplasmic domain of the VSV G from 29 amino acids (aa) to 9 aa or 1
aa, respectively (Publicover et al., 2004; Roberts et al., 1998).

Author Manuscript

Another approach to VSV attenuation was by rearrangement of the viral genes. Because
transcription for NS-NSVs is progressively reduced from 3′ to 5′ (see above), the change of
the gene order alters the protein expression levels and therefore reduces viral replication
(Wertz et al., 1998). As expected, VSV modified by gene rearrangement were greatly
attenuated in vitro and in vivo (Wertz et al., 1998).
The ability to create new vaccines by targeted attenuating changes of the viral genome was
also shown very early on for RABV. After intensive screening for pathogenicity markers,
the Dietzschold and Schnell laboratories showed that the RABV G protein as well as the
level of replication were major factors for RABV pathogenicity (Faber et al., 2007, 2004;
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McKenna et al., 2004; Pulmanausahakul et al., 2008). Based on these studies, candidate new
RABV vaccines were generated by introducing attenuating mutations into the G protein in
RABV vaccine strains (Gomme et al., 2011). However there are still major concerns about
using live vaccines in humans, and this is especially true for RABV. So other approaches,
such as gene deletion, have been used to create replication-deficient (Cenna et al., 2009;
Gomme et al., 2010) and highly replication-impaired RABV vaccines and vectors
(McGettigan et al., 2014).

Novel viral vectors based on NS-NSVs for immunizations against other
pathogens

Author Manuscript

Vaccines are one of the greatest achievements in medicine, as they protect us from
infectious diseases caused by natural pathogens. One to two inoculations of an attenuated
pathogen elicit humoral and cellular immune responses. Through reverse genetics specific
mutations with predictable phenotypes can be introduced into wild type or attenuated virus
strains, and their effects on the viral life cycle and pathogenicity can be verified. Based on
these modifications, new vectors for immunization against multiple infectious diseases are
being developed (for review see (Bukreyev et al., 2006)).
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RABV and VSV were not only the first NS-NSVs recovered from cDNA, they were also the
first NS-NSV to be developed as potential vectors. In the case of RABV, Mebatsion et al.
showed that the CAT marker gene can be expressed by RABV and is stable over more than
25 passages (Mebatsion et al., 1996). Similar findings were made simultaneously for VSV,
indicating not only stable expression of CAT but also that it did not did not affect the viral
life cycle. Moreover Schnell et al. showed that the minimal transcription start/stop found
within the VSV genome was sufficient to express a foreign gene (Schnell et al., 1996).
Research on several other NS-NSV expressing marker genes followed, and the researchers
showed similar results, particularly the highly stable expression.

Author Manuscript

Stable foreign gene expression by NS-NSV vectors may seem surprising considering the
high mutation rate of RNA polymerases in general (for review (Lauring et al., 2013)).
However, the helical nucleocapsids of NS-NSV form open structures that can grow in
length. These open structures do not impose the limitations inherent in the icosahedral
symmetry constraining the cargo volume, and thus the genome length, of most positive
strand viruses. Another source of genomic instability, genetic recombination, is minimized
by the fact that the genomic RNA of NS-NSV is always encapsidated, rather than naked as
the genome of plus-strand RNA viruses. Indeed, several studies have indicated that
recombination for NS-NSV is a very rare event, and so far it has only been described for
RSV (Collins et al., 2008; Spann et al., 2003).
Different NS-NSV-based vectors are now used as vaccine vectors to express protein of other
pathogens for immunization. Based on its ease of use, probably the most utilized vaccine
vector is VSV that has been developed for influenza virus (Roberts et al., 1998), RSV (Kahn
et al., 1999), human papilloma virus (Reuter et al., 2002), and henipaviruses (Kurup et al.,
2014), to just name a few. Most developed are the VSV vaccine vectors against human
immunodeficiency virus type 1 (HIV-1) and EBOV.
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For HIV-1, studies showed that VSV induces strong immune responses in mice and in
nonhuman primates (NHPs). However, as with other HIV-1 vaccine approaches, not all
animals were protected when a highly pathogenic challenge virus was used (Ramsburg et al.,
2004). These results were similar to those seen for the RABV-based vector, where the
immune responses were potent in mice (Lawrence et al., 2013) and NHPs and the
SIVmac251 challenge virus was controlled, but the RABV-based vector did not protect from
a highly pathogenic challenge virus (Faul et al., 2009). Nevertheless, a highly attenuated
form of the live-viral VSV vector is currently being tested in a phase I clinical trial for HIVAIDS (NCT01438606, Table 2). Other approaches for HIV-1 vaccines are based on NSNSV vectors such as MeV (Lorin et al., 2004) (NCT01320176, Table 2) or NDV (Carnero et
al., 2009). These vectors are desirable due to their proven efficacy and safety profiles (MeV)
(del Valle et al., 2007), or because they are replication-deficient in mammals (NDV). Both
MeV and NDV are currently in different stages of development as the search for an effective
HIV-1 vaccine continues.
At least six recently initiated clinical studies are assessing the efficacy of NS-NSV-based
vectors as vaccines against EBOV (Table 2; for review (Marzi and Feldmann, 2014)). This
effort is urgent due to the current public health crisis in West Africa. Multiple NHP studies
have proven that a recombinant VSV that has been deleted of its own G protein and is
instead expressing EBOV glycoprotein (GP) is efficient for preventing the disease (VSVΔGZEBOV, Table 2). A different approach is used for the RABV vector, which contains EBOV
GP in addition to RABV G. Because both proteins are incorporated into the RABV virions,
this vaccine can use an inactivated form of the virus, and therefore it should be a very safe
vaccine against EBOV and RABV (Blaney et al., 2013) infections, which are both a problem
in West Africa.
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Beside these two rhabdoviral vectors, human parainfluenza virus type 3 (hPIV3) (Bukreyev
et al., 2007) and the other paramyxovirus NDV (DiNapoli et al., 2010) expressing EBOV
GP are being developed as potential EBOV vaccines. The life cycle of these viruses should
allow intranasal or oral application, which is an advantage, and both of these viral vectors
might be safer than other live-viral vectors. However, concerns include preexisting
immunity for hPIV3 (a common human cold virus) and the lack of a strong anti-EBOV
immune response. As for all such live vectors, the challenge with these is to achieve a
balance between pathogenicity and immunogenicity.

Author Manuscript

Since the major target for NS-NSV antibodies is the glycoprotein or glycoproteins, these
have been exchanged to circumvent vector-specific neutralizing immune responses. For
VSV, the Rose laboratory used the G protein of the New Jersey strain to boost HIVimmunity elicited by a vector using the G protein from the non-cross-reactive VSV serotype
Indiana (Haglund et al., 2002). Importantly, the filovirus GPs can functionally replace VSV
G, a fact that is being used to develop Ebola vaccines (review see (Marzi and Feldmann,
2014)). Even if interference against successive immunization with vaccines containing
different GPs has not been documented, vector-induced cytotoxic T-cells directed against
the other VSV proteins may eventually affect vector efficiency.
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On the other hand, because an inactivated vaccine does result in infection, multiple
applications of an inactivated NS-NSV may not induce specific cytotoxic T-cells that
interfere with repeated vaccination. This has been confirmed for RABV: multiple
immunizations with inactivated virions containing foreign antigens are possible in the
presence of vector immunity (Hudacek et al., 2014; Papaneri et al., 2012).
In summary, different NS-NSV vectors hold great potential for the development of new
vaccines. It is important to note that certain advantages and disadvantages exist for each of
them. These include concerns regarding vector pathogenicity for live, replication-competent
vectors, and the potential need for multiple inoculations for replication-deficient or
inactivated vaccines. To develop multiple NS-NSV vector platforms is advisable because
multiple immunizations are not possible for most live viral vectors due the vector-directed
immune response that is induced after the first application.
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New Mononegavirales for oncolytic therapy

Author Manuscript

The concept of virotherapy originates from the observation of occasional tumor regressions
after natural viral infections (Kelly and Russell, 2007). While early virotherapy clinical trials
performed decades ago were poorly controlled, the advent of reverse genetics allowed
researchers to operate with viruses for which replication and gene expression could be easily
monitored. Current virotherapy clinical trials are based on viruses of nine different families,
including Paramyxoviridae and Rhabdoviridae within the order Mononegavirales (Miest
and Cattaneo, 2014). In these trials, therapeutic efficacy is assessed by well-defined
biological end points, host immunity is documented, and vectors and clinical trial protocols
are continuously improved (Liu et al., 2007; Russell et al., 2012). MeV and MuV infections,
among others, have occasionally been associated with cancer remissions (Kelly and Russell,
2007). For example, a so-called “spontaneous” complete regression of a large retro-orbital
Burkitt’s lymphoma tumor was documented after acute measles infection (Bluming and
Ziegler, 1971), and spontaneous cases of lymphoma remissions after acute measles have
been documented in hospitals of three continents (Kelly and Russell, 2007). MeV and MuV,
as the other “oncolytic” viruses, replicate preferentially in cancer cells because these
accumulate mutations in innate immunity and cell cycle control proteins. Most virus strains
used in current clinical trials are further targeted for selective replication in cancer cells
through genetic modifications (Cattaneo et al., 2008).
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Rather than attempting to cover all pre-clinical activities ongoing with recombinant
Mononegavirales, we discuss here in some depth three viruses that are already in cancer
clinical trials (Table 2): two genetically modified MeV and one VSV (Rhabdoviridae
family). As mentioned in the “vaccine” section, the modular nature of Mononegavirales
genomes, in combination with lack of icosahedral symmetry in viral particles, allows stable
expression of additional proteins, including those used for tracking or arming the
recombinant oncolytic viruses.

MV-CEA: development and validation
Approval of any new drug, including recombinant viruses, for patient delivery in clinical
trials is preceded by detailed FDA review of its manufacturing process, as well as
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comprehensive toxicology and biodistribution studies. A key first step for the development
of MeV-based cancer clinical trials was the generation of viruses for which distribution and
replication throughout the body can be monitored. Two approaches were taken to facilitate
infection monitoring. In the first one, the non-immunogenic soluble form of the
carcinoembryonic antigen (CEA) was expressed from an additional transcription unit (Peng
et al., 2002). The replication of this virus (MV-CEA, Table 2, top line) can be easily
documented by measuring CEA blood concentration by using an available clinical kit.
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To support a phase I trial of intraperitoneal administration of MV-CEA in patients with
recurrent ovarian cancer, biodistribution, toxicity, and efficacy studies were performed.
Biodistribution was characterized in MeV-sensitive Ifnarko-CD46Ge transgenic mice (Mrkic
et al., 1998). This analysis revealed that MV-CEA administered into the peritoneal cavity
efficiently infected peritoneal macrophages and these trafficked to abdominal draining
lymph nodes, as well as to the marginal zone of the spleen (Peng et al., 2003). Toxicology
studies were performed by intraperitoneal administration of large doses of MV-CEA in the
same model. These studies were essentially negative, with no significant toxicity
encountered at any dose level. Efficacy studies, which included dose–response analyses in
an intraperitoneal ovarian cancer xenograft model, allowed researchers to correlate the
different kinetic profiles of CEA expression with the different therapeutic outcomes (Peng et
al., 2006).
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Based on these studies a clinical trial was planned to determine the maximum tolerated dose
of intraperitoneal administration of MV-CEA (Table 2; clinicaltrials.gov identifier:
NCT00408590). The trial foresaw treatment of groups of three patients with 10-times
increasing doses of virus (103–109 infectious units), for a total of 21 patients. Because of the
requirement to completely evaluate the results obtained with a group of patients before
proceeding to the next one, the trial needed about 5 years to be completed. At the end of the
trial, it was concluded that the intraperitoneal treatment with MV-CEA was well tolerated
even at the highest doses. Interestingly, median survival of patients on study was 12 months,
comparing favorably to an expected median survival of 6 months in this patient population
(Galanis et al., 2010). Since the presence of neutralizing antibodies was suspected as being
the major limitation for efficacy, a follow up phase II clinical trial is planned to addresses
this limitation by delivering the virus through cell carriers. In this protocol (Table 2;
clinicaltrials.gov identifier: NCT02068794), patients with recurrent ovarian cancer are being
treated with mesenchymal stem cells infected with the other recombinant virus MV-NIS.

MV-NIS: monitoring the spread of oncolytic viruses in patients over time
Author Manuscript

Towards providing anatomical information about the location of virus-infected cells in
cancer patients, in vivo spread of an oncolytic virus should be monitored noninvasively over
time. To achieve this goal a recombinant virus coding for the human thyroidal natrium
iodine symporter (NIS) was generated (Dingli et al., 2004). NIS is a channel protein that
transports iodine, and its expression in the thyroid has been exploited for more than 50 years
in clinical practice for thyroid imaging with 123I, or thyroid ablation with 131I.
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MV-NIS infected cells can concentrate radioactive iodine from the bloodstream, enabling
noninvasive single photon emission computed tomography imaging of infection using 123I
or technetium. This approach has been used for high resolution monitoring of viral
replication in pre-clinical models (Miest et al., 2013). MV-NIS has also been used to
enhance the therapeutic potency of measles virotherapy by timed administration of 131I
(Dingli et al., 2004). Phase I clinical trials using MV-NIS have been initiated for ovarian
cancer, myeloma, mesothelioma, and head and neck cancer (Table 2; clinicaltrials.gov
identifier: NCT00408590, NCT00450814, NCT01503177 and NCT01846091).
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As MV-CEA, clinical grade MV-NIS was manufactured in a dedicated facility while
adhering to the principles of Good Manufacturing Practice (GMP). Since the intravenous
delivery of up to 1011 infectious units was foreseen, a new process was developed for the
manufacture of high titer virus stocks. This resulted in the production of pure and
homogeneous MV-NIS at a concentration of 109 infectious units/ml. Pre-clinical efficacy
studies were conducted in SCID mice bearing subcutaneous myeloma xenografts. Preclinical pharmacology and toxicology studies were conducted in MeV-susceptible IfnarkoCD46Ge transgenic mice, and in MeV-naïve squirrel monkeys (Myers et al., 2007).
Multiple myeloma was selected as target for the first systemically delivered oncolytic
vitotherapy clinical protocol because most patients have strongly reduced antibody titers to
many infectious agents, including MeV. The multiple myeloma phase I clinical trial
(NCT00450814) had a standard cohorts-of-3 design with a first dose level of 106 infectious
units of MV-NIS, increasing by 10-fold dose increments to a maximum feasible dose of
1011 infectious units. At the highest dose, the virus was infused into a superficial arm vein in
100 mL of normal saline over 60 min (Russell et al., 2014).
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Even if all eligible patients had relapsing myeloma refractory to approved therapies, Russell
et al. reported success: the first two measles seronegative patients treated at the highest dose
responded to therapy, and one experienced durable complete remission at all disease sites.
Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virusinfected plasmacytomas. Toxicities resolved within the first week after therapy (Russell et
al., 2014). This was the first well-documented remission from disseminated cancer after
systemic virotherapy. Based on this success, this clinical trial is being expanded at the
highest virus dose. The target group will include patients with minimal if any measlesneutralizing antibodies.

VSV-IFNβ: attenuating toxicity by interferon expression
Author Manuscript

A genetically modified VSV producing interferon-β (VSV-IFNβ) is the third recombinant
virus of the Mononegavirales order approved as experimental cancer therapeutic. A phase I
clinical trial to evaluate its safety in patients with liver cancer is recruiting (Table 2;
clinicaltrials.gov identifier: NCT01628640), and a clinical trial for head and neck cancer is
in preparation (Kurisetty et al., 2014). Several years ago it was shown that VSV induces
potent in vitro and in vivo tumor cytotoxic effects, and its oncolytic efficacy was
documented in a number of xenograft and syngeneic models (Barber, 2005). However,
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VSV-induced neurotoxicity initially limited the clinical development efforts with this agent
(Johnson et al., 2007).
To attenuate toxicity, a recombinant VSV that carries the gene encoding interferon-β was
developed. This virus showed an improved safety profile while keeping its oncolytic
potency (Obuchi et al., 2003; Willmon et al., 2009). The primary purpose of the current
phase clinical trial of liver cancer is to evaluate the safety of VSV-IFNβ. Although the
primary goal of any phase I study is to evaluate safety, patients may benefit clinically by
having shrinkage or stabilization of their tumor or reduction in their cancer related
symptoms, as observed in some of the MeV-based clinical protocols.

Next generation oncolytic viruses: enhancing efficacy
Author Manuscript

Viruses currently used in cancer clinical trials are safe at the highest doses achievable by
today’s manufacturing processes: adverse events beside fever and general flu-like symptoms
are rare (Liu et al., 2007). No transmission of an oncolytic virus from treated patients to
carers or other contacts has been noted, although shedding has been documented in the
urinary and respiratory tract (Galanis et al., 2010). While safety was consistently shown,
efficacy is limited. Thus the current key challenge is to develop more effective oncolytic
viruses that replicate with greater efficiency and specificity.
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Towards improving cancer specificity of Mononegavirales, three types of targeting are
possible: particles can be activated through cancer-specific proteases, cell entry can be redirected through cancer-specific cell surface proteins, and microRNA down-regulated in
cancer cells can be exploited. To improve efficacy viruses are armed through the expression
of either prodrug convertases that can activate cancer therapeutics, or ion channels that
enable radiosensitization, or immunostimulatory cytokines that induce antitumor immunity
(Miest and Cattaneo, 2014). To provide shielding from neutralizing antibodies different
envelopes are used sequentially. We discuss here selected examples of recombinant viruses
that illustrate different targeting or arming principles, or their combination towards a
specific cancer treatment.

Targeted viruses

Author Manuscript

The principle of cancer-specific in situ activation through proteases was established with the
Paramyxoviridae SeV (Kinoh et al., 2004) and MeV (Springfeld et al., 2006). This approach
is based on the modification of their fusion proteins, which require protease cleavage for
activation. Cleavage was made dependent on a matrix metalloprotease, MMP-2, which
recognizes and cleaves a specific hexapeptide sequence. MMP are zinc-dependent
endopeptidases that promote tumor progression by cleaving the extracellular matrix, and are
up-regulated in almost every type of human cancer (Egeblad and Werb, 2002).
A recombinant MeV was generated with a sequence recognized by MMP-2 engineered into
the fusion protein. This virus was unable to propagate unless it was added to cells expressing
MMP-2. In mice, the virus retained full oncolytic activity when inoculated into MMPpositive subcutaneous cancers, but unlike the wild-type virus, it did not kill susceptible mice
after intracranial inoculation (Springfeld et al., 2006). Thus the MMP-2 cleavable virus is
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safer than its standard precursor. While safety is not an issue in current clinical trials, future
one may consider more aggressive dosing. In these cases, enhanced tumor specificity by
MMP-selective activation may maintain an ideal safety profile.
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The principle of cancer-specific cell entry was also developed with Paramyxoviridae. In the
envelope of these viruses, receptor attachment and fusion functions are separated on two
proteins. In contrast, a single protein of other Mononegavirales families performs both
functions. Among the Paramyxoviridae, targeting of the MeV envelope is most advanced.
The MeV attachment protein (hemagglutinin, H) interacts with different receptors: the
primary receptor signaling lymphocyte activation molecule (SLAM, CD150) is used for
initial spread in lymphatic organs (Ferreira et al., 2010; Tatsuo et al., 2000), whereas the
adherens junction protein nectin-4 is subsequently used to gain access to the upper airways
epithelium and exit the host (Muhlebach et al., 2011). In addition, the vaccine strain has
gained the ability to use the ubiquitous membrane cofactor protein (MCP, CD46). The
footprints of all three receptors on H have been characterized structurally and functionally
(Mateo et al., 2014).
In 2000 MeV cell entry was targeted to designated receptors simply by adding small
specificity determinants to the H-protein (Schneider et al., 2000). It was then demonstrated
that even larger single chain antibodies could be used to target viral entry in cultivated cells
(Hammond et al., 2001), as well as in xenografts set in immunodeficient mice (Bucheit et
al., 2003). Availability of single chain antibodies against almost every cancer-relevant cell
surface protein allowed testing of many potential entry targets. Indeed MeV-based retargeting is versatile: many re-targeted viruses have been generated and shown to be
effective in different animal models of oncolysis (Nakamura et al., 2005).
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On the other hand, cell entry targeting may not be necessary for most cancer applications:
MV-CEA and MV-NIS can enter cells through CD46, which is over-expressed in many
cancer types (Russell and Peng, 2009). In view of this fact, and of the complex regulatory
requirements and large investments necessary to produce clinical grade viruses, specifically
entry re-targeted strains have not yet reached production stage. However, recent results
questioned whether CD46-dependent entry always favors efficient oncolysis: no direct
correlation between CD46 expression levels and therapeutic efficacy was observed in
clinical trials, and oncolytic ablation of certain lymphoma xenografts occurred only when
cell entry occurred through SLAM (Miest et al., 2013). Thus, entry targeting may soon be
re-prioritized.
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Based on positive results with other virus types, the principle of negative post-entry
targeting was established in the two Mononegavirales VSV and MeV (Edge et al., 2008;
Leber et al., 2011). In particular, since neuron-specific microRNA-7 is downregulated in
gliomas but highly expressed in normal brain tissue, a microRNA-sensitive MeV containing
target sites for this microRNA was engineered. Even though highly attenuated in presence of
microRNA-7, this virus retained full efficacy against glioblastoma xenografts. Furthermore,
microRNA-mediated inhibition protected transgenic mice susceptible to MeV infection from
a potentially lethal intracerebral challenge. Importantly, endogenous microRNA-7
expression in primary human brain resections tightly restricted replication and spread of
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microRNA-sensitive virus. Since the three targeting mechanisms discussed above are based
on different principles, they can be combined.

Armed viruses, and the pathway to clinical translation

Author Manuscript

While multiple targeting layers will yield viruses that replicate very selectively within
tumors, the main limitation of current clinical trials is efficacy. Cancer therapy efficacy can
be enhanced by the combination of different treatment modalities. Indeed, no single drug or
treatment will cure cancer, and most therapeutic regimens are based on combinations of
drugs, radiation, and surgery to maximize patient survival. Recombinant viruses armed with
specific genes may perform even better by integrating different components of current
cancer therapy regimens (Ottolino-Perry et al., 2010). For example, judiciously timed
administration of 131I can be used to enhance the therapeutic potency of virotherapy (Dingli
et al., 2004).
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A second example of this integrative approach is an armed and targeted virus for lymphoma
treatment. This virus was generated as an enhancer of FCR, a front-line treatment for certain
forms of non-Hodgkin lymphoma. The FCR regimen is based on cycles of treatment with
fludarabine phosphate, cyclophosphamide, and the anti-CD20 antibody Rituxan. As an
alternative to Rituxan, a CD20-targeted measles virus was considered. This virus was armed
with the prodrug convertase purine nucleotide phosphorylase, which converts fludarabine
phosphate to a highly diffusible substance that is capable of efficiently killing bystander
cells. The CD20-targeted and convertase-armed virus was shown to synergize with
fludarabine to achieve oncolytic efficacy after systemic inoculation in a mantle cell
lymphoma xenograft model (Ungerechts et al., 2007). Precise timing of cyclophosphamide,
virus, and fludarabine administration was shown to increase the window of therapeutic
opportunity (Ungerechts et al., 2010).
Finally, we note that the original MeV infectious cDNA, from which MV-CEA and MVNIS were derived, accidentally accumulated mutations in the innate immunity control
proteins that further attenuate viruses derived from it (Devaux et al., 2011, 2007). While this
over-attenuation may have contributed to the safety of MN-CEA and MV-NIS, it may also
have impacted their clinical efficacy.
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Phylogeny of the genera within the order Mononegavirales. Genera for which reverse
genetics systems have been established for at least one species are highlighted. The
phylogenetic tree was generated with phyloT (Letunic and Bork, 2007, 2011).
Abbreviations: B01 – Bornavirus; F01 – Cuevavirus; F02 – Ebolavirus; F03 –
Marburgvirus; N01 – Nyavirus; P01 – Aquaparamyxovirus; P02 – Avulavirus; P03 –
Ferlavirus; P04 – Henipavirus; P05 – Morbillivirus; P06 – Respirovirus; P07 – Rubulavirus;
P08 – Metapneumovirus; P09 – Pneumovirus; R01 – Cytorhabdovirus; R02 –
Ephemerovirus; R03 – Lyssavirus; R04 – Novirhabdovirus; R05 – Nucleorhabdovirus; R06
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– Perhabdovirus; R07 – Sigmavirus; R08 – Sprivivirus; R09 – Tibrovirus; R10 – Tupavirus;
R11 – Vesiculovirus.
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Fig. 2.

General genome organization of Mononegaviruses. Size of the genomes and individual
genes is proportional to their length.
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Transcription and replication of a NNSV shown for RABV. (A) The encapsidated negativestrand RNA (yellow) serves as a template for the polymerase complex. Transcription starts
with a short uncapped leader RNA (leRNA) from the 3′ end of the genomic RNA; this is
followed by the transcription of 5′ capped and polyadenylated mRNAs, which encode the
viral proteins (green). The polymerase complex stops at a signal sequence, ignores the
intergenic region (IGR) and restarts transcription at the transcription start signal sequence.
Subsequent attempts at transcription by the polymerase complex are not always successful;
therefore, attenuation of transcription occurs in the direction of 3′-5′ (transcription gradient).
(B) During replication, the polymerase complex ignores the transcription start/stop signals
within the RABV genome (yellow), rendering a full-length antigenomic RNA (green),
which is also encapsidated. The antigenomic RNA is encapsidated into the N protein along
with the genomic RNA. The synthesized antigenome serves then as a template for the
synthesis of additional copies of genomic RNA (yellow).
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Rescue systems currently developed for Mononegavirales. References of the first published rescues of the
respective species. N/A: No rescue system available as stated in the cited reference. ––: No rescue system
found in the literature.
Family

Subfamily

Genus

Species

Reverse
Genetics
established

Reference

Bornaviridae

B01 – Bornavirus

Borna disease virus

2005

Schneider et al. (2005)

Filoviridae

F01 – Cuevavirus

Lloviu cuevavirus

––

F02 – Ebolavirus

Zaire ebolavirus

2001

Volchkov et al. (2001)

F03 – Marburgvirus

Marburg marburgvirus

2006

Enterlein et al. (2006)

N01 – Nyavirus

Nyamanini nyavirus

2013

Herrel et al. (2013)

P01 – Aquaparamyxovirus

Atlantic salmon
paramyxovirus

––

P02 – Avulavirus

Newcastle disease virus

1999

P03 – Ferlavirus

Fer-de-Lance
paramyxovirus

––

P04 – Henipavirus

Hendra virus

2013

Marsh et al. (2013)

Nipah virus

2006

Yoneda et al. (2006)

Canine distemper virus

2000

Gassen et al. (2000)

Measles virus

1995

Radecke et al. (1995)

Rinderpest virus

1997

Baron and Barrett (1997)

Human parainfluenza
virus 1

2002

Newman et al. (2002)

Human parainfluenza
virus 3

1997

Hoffman and Banerjee
(1997)

Bovine parainfluenza virus 3

2000

Schmidt et al. (2000)

Sendai virus

1995

Garcin et al. (1995)

Human parainfluenza
virus 2

2001

Kawano et al. (2001)

Mumps virus

2000

Clarke et al. (2000)

Parainfluenza virus 5

1997

He et al. (1997)

P08 – Metapneumovirus

Human metapneumovirus

2004

Biacchesi et al. (2004)

P09 – Pneumovirus

Human respiratory
syncytial virus

1995

Collins et al. (1995)

Bovine respiratory
syncytial virus

1999

Buchholz et al. (1999)

R01 – Cytorhabdovirus

Lettuce necrotic yellows
virus

N/A

Kormelink et al. (2011)

R02 – Ephemerovirus

Bovine ephemeral fever
virus

––

R03 – Lyssavirus

Rabies virus

1994

Schnell et al. (1994)

R04 – Novirhabdovirus

Infectious hematopoietic
necrosis virus

2000

Biacchesi et al. (2000)

Viral hemorrhagic
septicemia virus

2010

Ammayappan et al.
(2011)

Snakehead rhabdovirus

2000

Johnson et al. (2000)

Nyamaviridae
Paramyxoviridae

Paramyxovirinae
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P05 – Morbillivirus

P06 – Respirovirus

Author Manuscript

P07 – Rubulavirus

Pneumovirinae

Rhabdoviridae

Author Manuscript
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Genus

Species

Reverse
Genetics
established

Reference

R05 – Nucleorhabdovirus

Potato yellow dwarf virus

N/A

Kormelink et al. (2011)

R06 – Perhabdovirus

Perch rhabdovirus

––

R07 – Sigmavirus

Drosophila melanogaster
sigmavirus

––

R08 – Sprivivirus

Spring viraemia of carp
virus

––

R09 – Tibrovirus

Tibrogargan virus

––

R10 – Tupavirus

Tupaia virus

––

R11 – Vesiculovirus

Vesicular stomatitis
Indiana virus

1995
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Selected Mononegavirales in clinical trials. Clinical trials can be found at https://clinicaltrials.gov/.
Virus strain

Purpose

Clinical trials

Respiratory syncytial virus
RSV ΔNS2 Δ1313 I1314L

Live-attenuated vaccine

NCT01893554: Safety and immune response in infants and children
(Phase I)

Respiratory syncytial virus
RSV cps2

Live-attenuated vaccine

NCT01852266: Safety and immune response in RSV-seronegative
infants and children (Phase I)

Measles virus
MV1-F4

Vectored vaccine

NCT01320176: Safety and dose-response of MeV vector expressing
HIV-1 clade B antigen in healthy adults (Phase I)

Vesicular stomatitis virus
VSV-Indiana HIV gag

Vectored vaccine

NCT01438606: Safety and immunogenicity in healthy, HIV-1-uninfected
adults (Phase I)

Vesicular stomatitis virus
VSVΔG-ZEBOV (BPSC1001)

Vectored vaccine

NCT02280408: Safety and immunogenicity of prime-boost in healthy
adults (Phase I)
NCT02283099: Safety, Tolerability and Immunogenicity of a Single
Ascending Dose (Phase I)

Author Manuscript

NCT02287480: Safety and immunogenicity in healthy adults (Phase I)
NCT02296983: Safety and immunogenicity in healthy adults in Kilifi,
Kenya (Phase I)
NCT02314923: Safety and immunogenicity in healthy adults (Phase I)
NCT02344407: Safety and immunogenicity in healthy adults in
Monrovia,
Liberia; comparison with chimpanzee adenoviral vector ChAd3-EBO Z
(Phase II)
Measles virus
MV-CEA

Oncolysis: Tracking

Measles virus
MV-NIS

Oncolysis: Tracking and Arming

NCT00408590: Ovarian cancer (Phase I) (Galanis et al., 2010)
NCT00390299: Recurrent glioblastoma multiforme (Phase I)
NCT00450814: Recurrent or refractory multiple myeloma (Phase II)
(Russell et al., 2014)
NCT02068794: Recurrent ovarian cancer cell carriers (Phase II)
NCT01503177: Malignant pleural mesothelioma (Phase I)
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NCT01846091: Recurrent or metastatic squamous cell carcinoma of the
head and neck (Phase I)
Vesicular stomatitis virus
VSV-IFNβ

Oncolysis: Selective Dis-Arming

NCT01628640: Hepatocellular carcinoma (Phase I)
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